Phase II study of vinorelbine in patients with hormone refractory prostate cancer

被引：0
|
作者：
Caty, A [1 ]
Oudard, S [1 ]
Humblet, Y [1 ]
Beauduin, M [1 ]
Suc, E [1 ]
Gil, T [1 ]
Rolland, F [1 ]
Houyau, P [1 ]
Sun, X [1 ]
Montcuquet, P [1 ]
Breza, J [1 ]
Favreau, E [1 ]
Tresca, P [1 ]
Chopin, D [1 ]
机构：
[1] CTR OSCAR LAMBRET,F-59020 LILLE,FRANCE
来源：
EUROPEAN JOURNAL OF CANCER | 1997年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：135 / 135
页数：1
相关论文
共 50 条
  • [31] A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer
    Bergan, RC
    Reed, E
    Myers, CE
    Headlee, D
    Brawley, O
    Cho, HK
    Figg, WD
    Tompkins, A
    Linehan, WM
    Kohler, D
    Steinberg, SM
    Blagosklonny, MV
    CLINICAL CANCER RESEARCH, 1999, 5 (09) : 2366 - 2373
  • [32] Phase II study of FK228 in patients with metastatic hormone refractory prostate cancer (HRPC)
    Molife, Rhoda
    Dearnaley, David
    Parker, Chris
    Patterson, Stephen
    Riggs, Charles
    Higano, Celestia
    Stadler, William M.
    McCulloch, William
    Shalaurov, Alex
    de Bono, Johann
    ANNALS OF ONCOLOGY, 2006, 17 : 149 - 149
  • [33] Phase I/II study of taxane and estramustine with samarium in patients with hormone refractory prostate cancer.
    Arnsmeier, SL
    Spies, S
    Shervin, D
    Pins, M
    Bergan, RC
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 439S - 439S
  • [34] A phase II trial of lapatinib in hormone refractory prostate cancer
    Whang, Y. E.
    Moore, C. N.
    Armstrong, A. J.
    Rathmell, W. K.
    Godley, P. A.
    Crane, J. M.
    Grigson, G. I.
    Morris, K.
    Watkins, C. P.
    George, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] Review of phase II hormone refractory prostate cancer trials
    Murphy, GP
    UROLOGY, 1999, 54 (6A) : 19 - 21
  • [36] Vinorelbine and prednisone are efficacy combination in hormone refractory metastatic prostate older cancer patients
    Tralongo, P
    Di Mari, A
    Conti, G
    Aiello, R
    Bollina, R
    Beretta, G
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 373 - 373
  • [37] A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer
    Dreicer, R
    Kemp, JD
    Stegink, LD
    Cardillo, T
    Davis, CS
    Forest, PK
    See, WA
    CANCER INVESTIGATION, 1997, 15 (04) : 311 - 317
  • [38] The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: A phase II feasibility study conducted by the Hellenic Cooperative Oncology Group
    Samelis, GF
    Kalofonos, H
    Adamou, A
    Kosmides, P
    Skarlos, D
    Aravantinos, G
    Kiamouris, C
    Adimchi, O
    Fountzilas, G
    Dimopoulos, AM
    UROLOGY, 2005, 66 (02) : 382 - 385
  • [39] Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer
    Abratt, RP
    Brune, D
    Dirnopoulos, MA
    Kliment, J
    Breza, J
    Selvaggi, FP
    Beuzeboc, P
    Demkow, T
    Oudard, S
    ANNALS OF ONCOLOGY, 2004, 15 (11) : 1613 - 1621
  • [40] Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer
    Kikuno, Nobuyuki
    Urakami, Shinji
    Nakamura, Shigeru
    Hiraoka, Takeo
    Hyuga, Taijyu
    Arichi, Naoko
    Wake, Kouji
    Sumura, Masahiro
    Yoneda, Tatsuaki
    Kishi, Hirofumi
    Shigeno, Kazushi
    Shiina, Hiroaki
    Igawa, Mikio
    EUROPEAN UROLOGY, 2007, 51 (05) : 1252 - 1258
12345